FrancophonIA/ELRC3.0 huggingface dataset:
English: The main efficacy criterion was the composite of cardiovascular death, hospitalization for acute MI or hospitalization for new onset or worsening heart failure.
Slovenian: Poglavitno merilo učinkovitosti je bil sestavljen izid srčno-žilne umrljivosti, hospitalizacije zaradi akutnega miokardnega infarkta in hospitalizacije zaradi novonastalega srčnega popuščanja ali njegovega poslabšanja.
English: The intake of the tablet during meals is recommended in order to decrease intra-individual variability in exposure (see section 4.2).
Slovenian: Priporočljivo je jemanje tablet v času obrokov za zmanjšanje nihanj v izpostavljenosti med posameznimi bolniki (glejte poglavje 4.2).
English: Additional efficacy of ivabradine in combination with dihydropyridine calcium channel blockers has not been established (see section 5.1).
Slovenian: Dodatne učinkovitosti ivabradina v kombinaciji z dihidropiridinskimi kalcijevimi antagonisti niso zasledili (glejte poglavje 5.1).
English: These data are consistent with the pharmacological effect of ivabradine related to its interaction with hyperpolarisation-activated Ih currents in the retina, which share extensive homology with the cardiac pacemaker If current.
Slovenian: Ti podatki so skladni s farmakološkim učinkom ivabradina, povezanim z njegovim medsebojnim delovanjem z mrežničnimi hiperpolarizacijsko sproženimi tokovi Ih, ki si delijo obširno homologijo s srčnim frekvenčno urejevalnim tokom If.
English: However, in the absence of extensive data, non urgent DC-cardioversion should be considered 24 hours after the last dose of ivabradine.
Slovenian: Toda ker ni obsežnejših podatkov, razmislite o neurgentni kardioverziji z enosmernim tokom v 24 urah po zadnjem odmerku ivabradina.
English: Preferred Term
Slovenian: Sprejeti izraz
English: The main pharmacodynamic property of ivabradine in humans is a specific dose dependent reduction in heart rate.
Slovenian: Poglavitna farmakološka lastnost ivabradina pri ljudeh je specifično od odmerka odvisno zniževanje srčne frekvence.
English: There was a significant improvement in NYHA class at last recorded value, 887 (28%) of patients on ivabradine improved versus 776 (24%) of patients on placebo (p=0.001).
Slovenian: Pri razredu NYHA v zadnji zabeleženi vrednosti je bilo značilno izboljšanje, 887 (28 %) bolnikom zdravljenih z ivabradinom se je stanje izboljšalo v primerjavi z izboljšanjem pri 776 (24 %) bolnikov, ki je prejemalo placebo (p=0,001).
English: In some cases (e.g. if you are elderly), your doctor may prescribe half the dose i.e., one half 5 mg tablet of Corlentor 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening.
Slovenian: Nekaterim bolnikom (na primer, če ste starejši) lahko zdravnik predpiše polovični odmerek, se pravi eno polovico 5 mg tablete (kar ustreza 2,5 mg ivabradina) zjutraj in eno polovico 5 mg tablete zvečer.
English: In particular, the additional benefit over 5 mg twice daily was established in a reference-controlled study versus atenolol: total exercise duration at trough was increased by about 1 minute after one month of treatment with 5 mg twice daily and further improved by almost 25 seconds after an additional 3-month period with forced titration to 7.5 mg twice daily.
Slovenian: Večji koristni učinek od odmerka 5 mg dvakrat na dan so zlasti dokazali v referenčni kontrolirani študiji v primerjavi z atenololom: skupno trajanje vadbe v času najmanjšega učinka se je povečalo za približno 1 minuto po enem mesecu zdravljenja z odmerkom 5 mg dvakrat na dan in še nadalje izboljšalo za skoraj 25 sekund po dodatnem 3-mesečnem obdobju z obveznim titriranjem na 7,5 mg dvakrat na dan.
English: Linearity/non linearity The kinetics of ivabradine is linear over an oral dose range of 0.5 - 24 mg.
Slovenian: Linearnost/nelinearnost Kinetika ivabradina je linearna v razponu peroralnih odmerkov od 0,5 do 24 mg.
English: Increased plasma concentrations of ivabradine may be associated with the risk of excessive bradycardia (see section 4.4).
Slovenian: Povečana koncentracija ivabradina v plazmi je lahko povezana s tveganjem prevelike bradikardije (glejte poglavje 4.4).
English: The usual recommended starting dose of ivabradine is 5 mg twice daily.
Slovenian: Običajni priporočeni začetni odmerek ivabradina je 5 mg dvakrat na dan.
English: When treatment modifications are made in chronic heart failure patients treated with ivabradine blood pressure should be monitored at an appropriate interval (see section 4.8).
Slovenian: Kadar pri bolnikih s kroničnim srčnim popuščanjem, zdravljenih z ivabradinom, spremenite zdravljenje, je potrebno v primernem intervalu spremljati krvni tlak (glejte poglavje 4.8).
English: D CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Slovenian: D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
English: At usual recommended doses, heart rate reduction is approximately 10 bpm at rest and during exercise.
Slovenian: Ob običajnih priporočenih odmerkih znižanje srčne frekvence znaša približno 10 utripov na minuto med mirovanjem in vadbo.
English: Fertility Studies in rats have shown no effect on fertility in males and females (see section 5.3).
Slovenian: Študije na podganah niso pokazale učinka na plodnost pri samcih in samicah (glejte poglavje 5.3).
English: Given that the heart rate may fluctuate considerably over time, serial heart rate measurements, ECG or ambulatory 24-hour monitoring should be considered when determining resting heart rate before initiation of ivabradine treatment and in patients on treatment with ivabradine when titration is considered.
Slovenian: Glede na to, da lahko srčna frekvenca precej niha, morate razmisliti o serijskem merjenju srčne frekvence, EKG in 24-urnem ambulantnem spremljanju, ko določate srčno frekvenco v mirovanju pred uvedbo zdravljenja z ivabradinom ter pri bolnikih, ki jemljejo ivabradin in pri katerih menite, da je potrebno titrirati odmerek.
English: Potassium-depleting diuretics (thiazide diuretics and loop diuretics): hypokalemia can increase the risk of arrhythmia.
Slovenian: Diuretiki, ki povzročijo izgubo kalija (tiazidni diuretiki in diuretiki zanke): hipokaliemija lahko poveča tveganje za aritmijo.
English: Since tablets contain lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Slovenian: Ker tablete vsebujejo laktozo, tega zdravila ne smejo jemati bolniki z redkimi dednimi težavami, kot so intoleranca za galaktozo, laponska oblika zmanjšane aktivnosti laktaze ali malabsorpcija glukoze ali galaktoze.
English: The average plasma concentration is 10 ng/ml (CV=38%) at steady-state.
Slovenian: Povprečna koncentracija v plazmi znaša 10 ng/ml (koeficient variacije = 38 %) v stanju dinamičnega ravnovesja.
English: Ivabradine should be used with caution in heart failure patients with NYHA functional classification IV due to limited amount of data in this population.
Slovenian: Ivabradin je potrebno pri bolnikih s srčnim popuščanjem IV. razreda po funkcijski razvrstitvi Newyorškega društva za srce (NYHA) uporabljati previdno, ker pri tej skupini bolnikov ni dovolj podatkov.
English: - Chronic heart failure in adult patients whose heart rate is over or equal to 75 beats per minute.
Slovenian: odraslih bolnikov s kroničnim srčnim popuščanjem in srčnim utripom višjim ali enakim 75 utripom na minuto.
English: Do not take Corlentor - if you are allergic to ivabradine or any of the other ingredients of this medicine (listed in section
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Corlentor Ne jemljite zdravila Corlentor - če ste alergični na ivabradin ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
English: They particularly occur within the first 2 to 3 months of treatment initiation.
Slovenian: Pojavljajo se predvsem v prvih 2 do 3
English: Ivabradine may cause transient luminous phenomena consisting mainly of phosphenes (see section 4.8).
Slovenian: Ivabradin lahko povzroča prehodne pojave svetlikanja, ki zajemajo predvsem fosfene (glejte poglavje 4.8).
English: The antianginal and anti-ischaemic effects of ivabradine were associated with dose-dependent reductions in heart rate and with a significant decrease in rate pressure product (heart rate x systolic blood pressure) at rest and during exercise.
Slovenian: Antianginozni in antiishemični učinek ivabradina je bil povezan z znižanjem srčne frekvence, odvisnim od odmerka ter s signifikantnim zmanjšanjem dvojnega produkta (srčna frekvenca x sistolični krvni tlak) med mirovanjem in vadbo.
English: The starting dose should not exceed one tablet of Corlentor 5 mg twice daily.
Slovenian: Začetni odmerek ne sme presegati ene tablete zdravila Corlentor 5 mg dvakrat na dan.
English: The maintenance dose should not exceed 7.5 mg twice daily.
Slovenian: Vzdrževalni odmerek ne sme presegati 7,5 mg dvakrat na dan.
English: The twice-daily dosing regimen of ivabradine gave uniform efficacy over 24 hours.
Slovenian: Režim odmerjanja ivabradina dvakrat na dan je omogočal enakomerno učinkovitost vseh 24 ur.
English: B CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription.
Slovenian: B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept.
English: A MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturers responsible for batch release Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, France Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co. Wicklow, Ireland Przedsiebiorstwo Farmaceutyczne ANPHARM S.A., ul.
Slovenian: Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, Francija Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co. Wicklow, Irska Przedsiebiorstwo Farmaceutyczne ANPHARM S.A., ul.
English: Ivabradine does not influence intracardiac conduction, contractility (no negative inotropic effect) or ventricular repolarisation: - in clinical electrophysiology studies, ivabradine had no effect on atrioventricular or intraventricular conduction times or corrected QT intervals; - in patients with left ventricular dysfunction (left ventricular ejection fraction (LVEF) between 30
Slovenian: Ivabradin ne vpliva na znotrajsrčno prevajanje, kontraktilnost (ni negativnega inotropnega učinka) ali repolarizacijo prekatov: - v kliničnih elektrofizioloških študijah ivabradin ni vplival na čase atrioventrikularnega ali intraventrikularnega prevajanja ali na interval QT s popravkom; - pri bolnikih z disfunkcijo levega prekata (iztisnim deležem levega prekata med 30 in 45 %) ivabradin ni imel nobenih škodljivih učinkov na iztisni delež levega prekata.
English: Caution should be exercised in patients with retinitis pigmentosa.
Slovenian: Pri bolnikih s pigmentoznim retinitisom morate biti previdni.
English: 5 How to store Corlentor Contents of the pack and other information
Slovenian: Shranjevanje zdravila Corlentor Vsebina pakiranja in dodatne informacije
English: Ivabradine must not be initiated in patients with a pre-treatment resting heart rate below 70 beats per minute (see section 4.3).
Slovenian: Ivabradina ne smete uvajati pri bolnikih, ki imajo pred zdravljenjem srčno frekvenco med mirovanjem pod 70 utripov na minuto (glejte poglavje 4.3).
English: Heart rate reduction, as caused by ivabradine, may exacerbate QT prolongation, which may give rise to severe arrhythmias, in particular Torsade de pointes.
Slovenian: Zniževanje srčne frekvence, ki ga povzroči ivabradin, lahko poslabša podaljšanje intervala QT, kar lahko povzroči hude aritmije, kot je Torsade de pointes.
English: The cardiac effects are specific to the sinus node with no effect on intra-atrial, atrioventricular or intraventricular conduction times, nor on myocardial contractility or ventricular repolarisation.
Slovenian: Učinki v srcu so specifični za sinusni vozel, brez delovanja na čase intraatrijskega, atrioventrikularnega ali intraventrikualrnega prevajanja, ali na kontraktilnost miokarda ali repolarizacijo prekatov.
English: The major active metabolite is the N-desmethylated derivative (S 18982) with an exposure about 40% of that of the parent compound.
Slovenian: Poglavitni aktivni presnovek je N-demetilirani derivat (S 18982) z izpostavljenostjo, ki znaša približno
English: All phosphenes resolved during or after treatment, of which a majority (77.5%) resolved during treatment.
Slovenian: Vsi fosfeni so ponehali med zdravljenjem ali po njem, in sicer večina med zdravljenjem
English: A sustained reduction of heart rate was demonstrated in patients treated with ivabradine for at least one year (n = 713).
Slovenian: Pri bolnikih, ki so ivabradin jemali najmanj 1 leto, so dokazali vztrajno znižanje srčne frekvence (n = 713).
English: Ivabradine is not effective in the treatment or prevention of cardiac arrhythmias and likely loses its efficacy when a tachyarrhythmia occurs (eg.
Slovenian: Srčne aritmije Ivabradin ni učinkovit pri zdravljenju ali preprečevanju srčnih aritmij in verjetno izgubi učinkovitost ob pojavu tahiartimij (na primer ventrikularne ali supraventrikularne tahikardije).
English: Corlentor contains lactose
Slovenian: Zdravilo Corlentor vsebuje laktozo.
English: - Renal impairment: the impact of renal impairment (creatinine clearance from 15 to 60 ml/min) on ivabradine pharmacokinetic is minimal, in relation with the low contribution of renal clearance (about 20 %) to total elimination for both ivabradine and its main metabolite S 18982 (see section
Slovenian: - Bolniki z ledvično okvaro: učinek ledvične okvare (očistek kreatinina od 15 do 60 ml/min) na farmakokinetiko ivabradina je minimalen, kar je povezano z majhnim prispevkom ledvičnega očistka (približno 20 %) k skupnemu izločanju tako ivabradina kot njegovega poglavitnega presnovka S 18982
English: NAME OF THE MARKETING AUTHORISATION HOLDER Les Laboratoires Servier
Slovenian: IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Les Laboratoires Servier
English: Heart failure must be stable before considering ivabradine treatment.
Slovenian: Kronično srčno popuščanje Srčno popuščanje naj bo stabilno, preden se odločite za zdravljenje z ivabradinom.
English: Contra-indication of concomitant use
Slovenian: Kontraindikacije za sočasno jemanje
English: Treatment must be discontinued if heart rate remains below 50 bpm or symptoms of bradycardia persist despite dose reduction.
Slovenian: Zdravljenje morate prekiniti, če ostane srčna frekvenca pod 50 utripov na minuto ali če simptomi bradikardije vztrajajo kljub zmanjšanju odmerka.
English: Concomitant use with precaution
Slovenian: Sočasno jemanje, ki zahteva posebno previdnost
English: Lack of benefit on clinical outcomes in patients with symptomatic chronic stable angina pectoris Ivabradine is indicated only for symptomatic treatment of chronic stable angina pectoris because ivabradine has no benefits on cardiovascular outcomes (e.g. myocardial infarction or cardiovascular death ) (see section 5.1).
Slovenian: Pomanjkanje koristi na klinične izide pri bolnikih s simptomatsko kronično angino pektoris Ivabradin je indiciran samo za simptomatsko zdravljenje kronične stabilne angine pektoris, ker nima koristi na srčno-žilne izide (npr. miokardni infarkt ali srčno-žilno smrt) (glejte poglavje 5.1).
English: The possible occurrence of such luminous phenomena should be taken into account when driving or using machines in situations where sudden variations in light intensity may occur, especially when driving at night.
Slovenian: Možen nastanek tovrstnih pojavov svetlikanja morate upoštevati pri vožnji ali upravljanju s stroji v pogojih, kjer se lahko nenadno spreminja jakost svetlobe,
English: The usual recommended starting dose is one tablet of Corlentor 5 mg twice daily increasing if necessary to one tablet of Corlentor 7.5 mg twice daily.
Slovenian: Običajen priporočljiv začetni odmerek je ena tableta zdravila Corlentor 5 mg dvakrat na dan, kar lahko povečate na eno tableto zdravila Corlentor 7,5 mg dvakrat na dan, če je potrebno.
English: The study showed no difference in the rate of the primary composite outcome in the ivabradine group by comparison to the placebo group (relative risk ivabradine:placebo 1.00, p=0.945).
Slovenian: Študija ni pokazala razlik v stopnji poglavitnega sestavljenega izida med ivabradinom in placebom (sorazmerno tveganje ivabradin : placebo 1,00; p = 0,945).
English: Special populations - Older people: no pharmacokinetic differences (AUC and Cmax) have been observed between elderly (≥ 65 years) or very elderly patients (≥ 75 years) and the overall population (see section
Slovenian: Posebne skupine bolnikov - Starejši ljudje: med starejšimi (≥ 65 let) ali najstarejšimi (≥ 75 let) bolniki in celotno populacijo niso opazili razlik v farmakokinetiki (površini pod krivuljo (AUC) ter največji koncentraciji v plazmi)
English: It is also used in combination with beta-blockers in adult patients whose condition is not fully controlled with a beta-blocker.
Slovenian: Uporablja se tudi v kombinaciji z antagonisti receptorjev beta pri odraslih bolnikih, ki z antagonistom receptorjev beta nimajo popolnoma nadzorovanega stanja.
English: Inversely, potent inhibitors and inducers may substantially affect ivabradine plasma concentrations (see section 4.5).
Slovenian: Za razliko pa lahko močni zaviralci in spodbujevalci izrazito vplivajo na koncentracije ivabradina v plazmi (glejte poglavje 4.5).
English: Other secondary endpoints: - All cause death - Death from HF - Hospitalisation for any cause - Hospitalisation for CV reason
Slovenian: - smrt zaradi različnih vzrokov - smrt zaradi odpovedi srca - hospitalizacija zaradi kateregakoli vzroka - hospitalizacija zaradi srčno-žilnega vzroka
English: Patients with hypotension
Slovenian: Bolniki s hipotenzijo
English: In patients treated with ivabradine the risk of developing atrial fibrillation is increased (see section 4.8).
Slovenian: Bolniki, ki jemljejo ivabradin, imajo povečano tveganje za razvoj atrijske fibrilacije (glejte poglavje 4.8).
English: The reduction in the primary endpoint was observed consistently irrespective of gender, NYHA class, ischaemic or non-ischaemic heart failure aetiology and of background history of diabetes or hypertension.
Slovenian: Zmanjšanje primarnega končnega izida je bilo opaženo vedno neodvisno od spola, funkcijskega razreda NYHA, srčnega popuščanja ishemičnega ali neishemičnega izvora in diabetesa ali hipertenzije v anamnezi.
English: INFORMATION IN BRAILLE CORLENTOR 5 mg
Slovenian: PODATKI V BRAILLOVI PISAVI CORLENTOR 5 mg
English: Do not take Corlentor if you are able to become pregnant unless you use reliable contraceptive measures (see “Do not take Corlentor”).
Slovenian: Če ste ženska v rodni dobi ne smete jemati zdravila Corlentor, razen če uporabljate zanesljive kontracepcijske metode (glejte “Ne jemljite zdravila Corlentor”).
English: About chronic heart failure :
Slovenian: O kroničnem srčnem popuščanju:
English: After dose reduction, heart rate should be monitored (see section 4.4).
Slovenian: Po zmanjšanju odmerka morate spremljati srčno frekvenco (glejte poglavje 4.4).
English: The concomitant use of CYP3A4 inducing medicinal products may require an adjustment of the dose of ivabradine.
Slovenian: Sočasno jemanje zdravil, ki spodbujajo citokrom P450 3A4, lahko zahteva prilagajanje odmerka ivabradina.
English: 4.4 Special warnings and precautions for use
Slovenian: 4.4 Posebna opozorila in previdnostni ukrepi Posebna opozorila
English: High exposures to ivabradine that may occur when ivabradine is given in combination with strong CYP3A4 inhibitors may result in an excessive decrease in heart rate although this risk is reduced with moderate CYP3A4 inhibitors (see sections 4.3, 4.4 and 4.5).
Slovenian: Velika izpostavljenost ivabradinu, ki lahko nastaja ob jemanju ivabradina v kombinaciji z močnimi zaviralci citokroma P450 3A4, lahko povzroči preveliko znižanje srčne frekvence, medtem ko je ob zmernih zaviralcih citokroma P450 3A4 tovrstno tveganje zmanjšano (glejte poglavja 4.3, 4.4 in 4.5).
English: Verapamil, diltiazem or strong CYP 3A4 inhibitors were received by 7.1% of patients during the study.
Slovenian: Verapamil, diltiazem ali močne zaviralce citokroma P450 3A4 je med spremljanjem prejemalo 7,1 % bolnikov.
English: A specific study to assess the possible influence of ivabradine on driving performance has been performed in healthy volunteers where no alteration of the driving performance was evidenced.
Slovenian: Pri zdravih prostovoljcih so izvedli specifično študijo o možnem učinku ivabradina na sposobnost vožnje in niso zasledili, da bi se spremenila.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/05/317/008-014
Slovenian: ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/05/317/008-014
English: Pharmacokinetic interactions
Slovenian: Farmakokinetična medsebojna delovanja
English: Do not use this medicine after the expiry date which is stated on the carton and blister after ‘EXP'.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu za oznako EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
English: A large outcome study, BEAUTIFUL, was performed in 10917 patients with coronary artery disease and left ventricular dysfunction (LVEF<40%) on top of optimal background therapy with 86.9% of patients receiving beta-blockers.
Slovenian: Obsežna študija o izidih BEAUTIFUL je zajela 10.917 bolnikov s koronarno arterijsko boleznijo in disfunkcijo levega prekata (iztisni delež levega prekata < 40 %), ki so že prejemali optimalno osnovno zdravljenje, kar je pri 86,9 % bolnikov pomenilo antagoniste adrenergičnih receptorjev beta.
English: If heart rate is between 50 and 60 bpm, the dose of 5 mg twice daily should be maintained.
Slovenian: Če je srčna frekvenca med 50 in 60 utripov na minuto, je potrebno ohraniti odmerek 5 mg dvakrat na dan.
English: Moderate CYP3A4 inhibitors: specific interaction studies in healthy volunteers and patients have shown that the combination of ivabradine with the heart rate reducing agents diltiazem or verapamil resulted in an increase in ivabradine exposure (2 to 3 fold increase in AUC) and an additional heart rate reduction of 5 bpm.
Slovenian: Zmerni zaviralci citokroma P450 3A4: specifične študije o medsebojnih delovanjih pri zdravih prostovoljcih in bolnikih so pokazale, da je kombinacija ivabradina z zdravili, ki znižujejo srčno frekvenco, kot sta diltiazem ali verapamil, povečala izpostavljenost ivabradinu (2- do 3-kratno povečanje površine pod krivuljo (AUC)) ter dodatno znižala srčno frekvenco za 5 utripov na minuto.
English: Use in patients with a low heart rate
Slovenian: Uporaba pri bolnikih z nizko srčno frekvenco
English: In a 725-patients randomised placebo-controlled study, ivabradine did not show additional efficacy on top of amlodipine at the trough of drug activity (12 hours after oral intake) while an additional efficacy was shown at peak (3-4 hours after oral intake).
Slovenian: V randomizirani, s placebom nadzorovani študiji pri 725 bolnikih ivabradin kot dodatek amlodipinu ni pokazal dodatne učinkovitosti v času najmanjšega učinka (12 ur po peroralnem jemanju), medtem ko so v času največjega učinka (3 do 4 ure po peroralnem jemanju) dodatno učinkovitost zasledili.
English: Ivabradine is rapidly and almost completely absorbed after oral administration with a peak plasma level reached in about 1 hour under fasting condition.
Slovenian: Ivabradin se po peroralnem jemanju hitro in skoraj v celoti absorbira ter doseže največjo koncentracijo v plazmi po približno 1 uri v pogojih na tešče.
English: INFORMATION IN BRAILLE CORLENTOR 7.5 mg
Slovenian: PODATKI V BRAILLOVI PISAVI CORLENTOR 7,5 mg
English: This increase in heart rate can cause the chest pain in people who suffer from angina.
Slovenian: Tovrstno povečanje srčne frekvence lahko pri bolnikih z angino pektoris povzroča bolečine v prsih.